Investor
Forefront Analytics, LLC
CIK 0001696802 · filed 2026-02-17 · SEC filing
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Ishares Tr | — | 211.2K | $20.1M | 17.7% | — | Held |
| Ishares Inc | — | 363.7K | $16.1M | 14.2% | — | Held |
| Ishares Tr | — | 50.6K | $12.7M | 11.2% | — | Held |
| Vanguard Intl Equity Index F | — | 181.1K | $9.74M | 8.6% | — | Held |
| Ishares Tr | — | 69.3K | $8.43M | 7.4% | — | Held |
| Vanguard Tax-Managed Fds | — | 123.2K | $7.7M | 6.8% | — | Held |
| Nushares Etf Tr | — | 141.4K | $6.37M | 5.6% | — | Held |
| Dbx Etf Tr | — | 127.9K | $6.15M | 5.4% | — | Held |
| Flexshares Tr | — | 23K | $4.72M | 4.2% | — | Held |
| Ishares Tr | — | 4.71K | $3.22M | 2.8% | — | Held |
| Nvidia Corp | NVDA | 14K | $2.61M | 2.3% | — | Held |
| Ishares Core 30 70 Con | — | 58.7K | $2.35M | 2.1% | — | Held |
| Ishares Inc | — | 60.2K | $2.09M | 1.8% | — | Held |
| Jpmorgan Chase & Co. | — | 3.35K | $1.08M | 1.0% | — | Held |
| Wisdomtree Tr | — | 17.8K | $1.01M | 0.9% | — | Held |
| First Tr Exchange-Traded Fd | — | 18.4K | $698K | 0.6% | — | Held |
| Vanguard Index Fds | — | 3.46K | $661.8K | 0.6% | — | Held |
| Ishares Tr | — | 4.74K | $566K | 0.5% | — | Held |
| Deere & Co | DE | 1.13K | $528K | 0.5% | — | Held |
| Edwards Lifesciences Corp | EW | 6.11K | $521.1K | 0.5% | — | Held |
| Incyte Corp | INCY | 5.2K | $513.4K | 0.5% | — | Held |
| Unitedhealth Group Inc | UNH | 1.45K | $479.2K | 0.4% | — | Held |
| Pfizer Inc | PFE | 19.1K | $475.7K | 0.4% | — | Held |
| Proshares Tr | — | 8.15K | $471.8K | 0.4% | — | Held |
| Abbott Labs | ABT | 3.76K | $470.6K | 0.4% | — | Held |
| Medtronic Plc | MDT | 4.28K | $411.1K | 0.4% | — | Held |
| Proshares Tr | — | 7.98K | $375.1K | 0.3% | — | Held |
| Thermo Fisher Scientific Inc. | TMO | 586 | $339.5K | 0.3% | — | Held |
| Regeneron Pharmaceuticals, Inc. | REGN | 427 | $329.4K | 0.3% | — | Held |
| Ishares Tr | — | 3.29K | $265K | 0.2% | — | Held |
| Ishares Tr | — | 2.23K | $245K | 0.2% | — | Held |
| Ishares Tr | — | 3.97K | $244K | 0.2% | — | Held |
| Philip Morris Intl Inc | — | 1.44K | $230K | 0.2% | — | Held |
| Ishares Tr | — | 2.02K | $223K | 0.2% | — | Held |
| Mirum Pharmaceuticals, Inc. | MIRM | 2.66K | $210.3K | 0.2% | — | Held |
| Danaher Corporation | — | 915 | $209.4K | 0.2% | — | Held |
| Zura Bio Ltd | ZURA | 19.6K | $102.6K | 0.1% | — | Held |
| Bicycle Therapeutics Plc | BCYC | 13.4K | $94.7K | 0.1% | — | Held |
| CytomX Therapeutics, Inc. | CTMX | 18.7K | $79.7K | 0.1% | — | Held |
| Nkarta, Inc. | NKTX | 40.7K | $75.3K | 0.1% | — | Held |
| Geron Corp | GERN | 51.3K | $67.7K | 0.1% | — | Held |
| Annexon, Inc. | ANNX | 13.2K | $66.4K | 0.1% | — | Held |
| Mereo Biopharma Group Plc | MREO | 31.8K | $13.2K | 0.0% | — | Held |
Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.